European Randomised Study of Screening for Prostate Cancer ( <scp>ERSPC</scp> ) risk calculators significantly outperform the Prostate Cancer Prevention Trial ( <scp>PCPT</scp> ) 2.0 in the prediction of prostate cancer: a multi‐institutional study

Abstract

The performance of the risk calculators in the present cohort shows that the ERSPC-RC is a superior tool in the prediction of PCa; however the performance of the ERSPC-RC in this population does not yet warrant its use in clinical practice. The incorporation of the PHI score into the ERSPC-PHI risk calculator allowed each patient's risk to be more accurately quantified. Individual patient risk calculation using the ERSPC-PHI risk calculator can be undertaken in order to allow a systematic approach to patient risk stratification and to aid in the diagnosis of PCa.